Specificity and mechanism-of-action of the JAK2 tyrosine kinase inhibitors ruxolitinib and SAR302503 (TG101348)

Leukemia. 2014 Feb;28(2):404-7. doi: 10.1038/leu.2013.205. Epub 2013 Jul 4.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Janus Kinase 2 / antagonists & inhibitors
  • Janus Kinase 2 / chemistry*
  • Models, Molecular
  • Molecular Conformation
  • Protein Binding
  • Protein Kinase Inhibitors / chemistry*
  • Protein Kinase Inhibitors / pharmacology
  • Pyrrolidines / chemistry*
  • Pyrrolidines / pharmacology
  • Sulfonamides / chemistry*
  • Sulfonamides / pharmacology

Substances

  • Protein Kinase Inhibitors
  • Pyrrolidines
  • Sulfonamides
  • Fedratinib
  • Janus Kinase 2